Treatment Information

Back

Ovarian Cancer treatment details. Hormone.

Christie Hospital, Manchester, United Kingdom.

Survival: monthsCountry:United Kingdom
Toxiciy Grade:2City/State/Province:Manchester
Treatments:HormoneHospital:Christie Hospital
Drugs:Journal:Link
Date:Sep 2005

Description:

Patients: This phase I/II study involved a total of 26 women with recurrent epithelial ovarian cancer. The median age was 63.

Treatment: The treatment consisted of two hormone therapy agents - tamoxifen and goserelin (Zoladex).

Toxicity: No grade 3/4 toxicities were reported. Grade 2 toxicities included hot flushes.

Results: Median survival was 13.6 months.

Support: The study was "supported by a generous grant from Astra-Zeneca." Astra-Zeneca manufactures or markets tamoxifen and zoladex.

Correspondence: J. Hasan, MD




Back